Compare Sun Pharma with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ORCHID PHARMA LTD - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ORCHID PHARMA LTD SUN PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 27.3 -0.5 - View Chart
P/BV x 2.4 0.1 2,001.0% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 SUN PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
ORCHID PHARMA LTD
Sep-13
SUN PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs679194 349.9%   
Low Rs37535 1,072.6%   
Sales per share (Unadj.) Rs121.1276.5 43.8%  
Earnings per share (Unadj.) Rs13.4-79.2 -16.9%  
Cash flow per share (Unadj.) Rs20.7-43.5 -47.6%  
Dividends per share (Unadj.) Rs2.750-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs172.653.9 320.0%  
Shares outstanding (eoy) m2,399.2670.45 3,405.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.40.4 1,050.6%   
Avg P/E ratio x39.4-1.4 -2,726.0%  
P/CF ratio (eoy) x25.5-2.6 -967.1%  
Price / Book Value ratio x3.12.1 143.9%  
Dividend payout %20.60-   
Avg Mkt Cap Rs m1,264,6508,067 15,677.8%   
No. of employees `00017.52.8 625.0%   
Total wages/salary Rs m59,6712,527 2,361.3%   
Avg. sales/employee Rs Th16,608.16,956.1 238.8%   
Avg. wages/employee Rs Th3,409.6902.5 377.8%   
Avg. net profit/employee Rs Th1,833.8-1,993.0 -92.0%   
INCOME DATA
Net Sales Rs m290,65919,477 1,492.3%  
Other income Rs m10,255407 2,518.4%   
Total revenues Rs m300,91419,884 1,513.3%   
Gross profit Rs m63,0761,103 5,720.7%  
Depreciation Rs m17,5332,519 696.0%   
Interest Rs m5,5535,227 106.2%   
Profit before tax Rs m50,246-6,236 -805.7%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,144511 -2,376.5%   
Tax Rs m6,009-125 -4,799.4%   
Profit after tax Rs m32,093-5,580 -575.1%  
Gross profit margin %21.75.7 383.3%  
Effective tax rate %12.02.0 595.7%   
Net profit margin %11.0-28.7 -38.5%  
BALANCE SHEET DATA
Current assets Rs m310,69211,014 2,820.8%   
Current liabilities Rs m173,39632,060 540.8%   
Net working cap to sales %47.2-108.1 -43.7%  
Current ratio x1.80.3 521.6%  
Inventory Days Days9995 104.4%  
Debtors Days Days11234 332.5%  
Net fixed assets Rs m232,47729,440 789.7%   
Share capital Rs m2,399705 340.6%   
"Free" reserves Rs m411,6912,043 20,155.3%   
Net worth Rs m414,0913,800 10,897.4%   
Long term debt Rs m15,2269,018 168.8%   
Total assets Rs m646,93846,510 1,391.0%  
Interest coverage x10.0-0.2 -5,203.6%   
Debt to equity ratio x02.4 1.5%  
Sales to assets ratio x0.40.4 107.3%   
Return on assets %5.8-0.8 -765.6%  
Return on equity %7.8-146.9 -5.3%  
Return on capital %10.2-3.7 -272.3%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m66,0257,513 878.8%   
Fx outflow Rs m38,6105,649 683.5%   
Net fx Rs m27,4151,865 1,470.4%   
CASH FLOW
From Operations Rs m21,9651,682 1,306.1%  
From Investments Rs m-6,813-9,860 69.1%  
From Financial Activity Rs m-27,3056,644 -411.0%  
Net Cashflow Rs m-8,442-1,535 549.9%  

Share Holding

Indian Promoters % 63.7 32.3 197.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 4.6 111.5%  
FIIs % 23.0 3.3 697.0%  
ADR/GDR % 0.0 4.6 -  
Free float % 8.3 55.3 15.0%  
Shareholders   133,026 84,811 156.8%  
Pledged promoter(s) holding % 0.5 54.9 1.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling, Key Q2FY20 Results, and Top Cues in Focus Today(Pre-Open)

India share markets ended their day deep in the red yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Oct 22, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS